Immune Gene Expression Signature in Treg Enriched Tumor Samples
US-2020388348-A1 · Dec 10, 2020 · US
HDAC inhibitors for use with NK cell based therapies
US12427152B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12427152-B2 |
| Application number | US-201716317766-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jul 14, 2017 |
| Priority date | Jul 15, 2016 |
| Publication date | Sep 30, 2025 |
| Grant date | Sep 30, 2025 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Provided are methods and compositions for the treatment of cancer. The methods comprise administering to a subject an HDAC inhibitor and an immunotherapeutic agent. In certain instances the immunotherapeutic is an NK cell or a chimeric antigen receptor NK cell.
First claim
Opening claim text (preview).
What is claimed is: 1. A method for treating an androgen-independent prostate cancer in an individual afflicted with the androgen-independent prostate cancer, the method comprising administering to the individual afflicted with the androgen-independent prostate cancer: a) CHR-3996 (2-(6-{[(6-Fluoroquinolin-2-yl)methyl]amino}-3-azabicyclo[3.1.0]hex-3-yl)-N-hydroxypyrimidine-5-carboxamide); and b) a primary human NK cell. 2. The method of claim 1 , wherein CHR-3996 is administered orally. 3. The method of claim 1 , wherein CHR-3996 is administered at a dose of less than 40 mg per day. 4. The method of claim 1 , wherein CHR-3996 is administered at a dose of less than 20 mg per day. 5. The method of claim 1 , wherein CHR-3996 is administered prior to the administration of the primary human NK cell. 6. The method of claim 1 , wherein CHR-3996 is administered during the administration of the primary human NK cell. 7. The method of claim 1 , wherein CHR-3996 is administered after the administration of the primary human NK cell.
Assignees
Inventors
Classifications
comprising antibodies · CPC title
against proteinaceous materials, e.g. enzymes, hormones, lymphokines · CPC title
Non-condensed quinolines and containing further heterocyclic rings · CPC title
Mouth and digestive tract, i.e. intraoral and peroral administration · CPC title
for herpes viruses · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US12427152B2 cover?
- Provided are methods and compositions for the treatment of cancer. The methods comprise administering to a subject an HDAC inhibitor and an immunotherapeutic agent. In certain instances the immunotherapeutic is an NK cell or a chimeric antigen receptor NK cell.
- Who is the assignee on this patent?
- Viracta Therapeutics Inc, Nantkwest Inc
- What technology area does this patent fall under?
- Primary CPC classification A61K31/522. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Sep 30 2025 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 12 related publications on this page (citations in our corpus or others sharing the same primary CPC).